Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Short term Debt (2022 - 2025)

Axsome Therapeutics' Short term Debt history spans 4 years, with the latest figure at $70.0 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 744.9% year-over-year to $70.0 million; the TTM value through Dec 2025 reached $70.0 million, up 744.9%, while the annual FY2025 figure was $70.0 million, 744.9% up from the prior year.
  • Short term Debt for Q4 2025 was $70.0 million at Axsome Therapeutics, up from $9.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $70.0 million in Q4 2025 and bottomed at $5.9 million in Q4 2022.
  • The 4-year median for Short term Debt is $7.0 million (2022), against an average of $11.4 million.
  • The largest annual shift saw Short term Debt fell 4.69% in 2023 before it skyrocketed 744.9% in 2025.
  • A 4-year view of Short term Debt shows it stood at $5.9 million in 2022, then rose by 8.59% to $6.4 million in 2023, then grew by 29.31% to $8.3 million in 2024, then surged by 744.9% to $70.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Short term Debt are $70.0 million (Q4 2025), $9.7 million (Q3 2025), and $9.2 million (Q2 2025).